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013; revised manuscript received December 28,Hypertension is a major risk factor for cardiovascular disease,
with established complications of stroke, myocardial
infarction, and heart failure (1). Despite the high worldwide
prevalence of hypertension and known clinical consequences,
the underlying causes of hypertension are not fully eluci-
dated. Identifying novel risk factors for hypertension is
important for understanding the etiology of and the sug-
gestion of possible new treatment targets to reduce the high
burden of morbidity and mortality.
Disturbances in vitamin D and parathyroid hormone
(PTH) metabolism are plausibly related to hypertension
through diverse mechanisms. Primary hyperparathyroidism
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1215is long recognized for its association with prevalent hyperten-
sion, and more recent prospective studies demonstrate as-
sociations of greater serum PTH concentrations with higher
blood pressure in men (2) and with incident hypertension in
the general population (3,4). Vitamin D deﬁciency promotes
secondary hyperparathyroidism, increases the secretion of
aldosterone, and stimulates the renin-angiotensin system (5).
Lower serum 25-hydroxyvitamin D (25[OH]D) concentra-
tions are associated with higher blood pressure and hyper-
tension risk (6,7). Furthermore, disturbances in both serum
25(OH)D and PTH are related to arterial stiffness and
vascular dysfunction, which are strong determinants of
future hypertension (8).
Despite intriguing potential physiologic connections of
biomarkers of vitamin D and PTH metabolism with blood
pressure, few studies have prospectively evaluated associa-
tions of serum 25(OH)D and PTH concentrations with the
initial development of hypertension (3,4,6,7,9,10). Previous
studies have assessed single biomarkers, used self-reported
hypertension data, did not investigate both sexes, or were
conducted among racially homogenous populations. Under-
standing prospective associations of vitamin D and PTH
with the onset of hypertension would provide insight into
disease mechanisms and may be important for developing
future preventive strategies.
We measured serum 25(OH)D and PTH concentrations
in 3,002 individuals from a community-based, middle-aged,
multi ethnic cohort free of clinical hypertension and car-
diovascular diseases. We hypothesized that lower serum
25(OH)D and higher serum PTH concentrations would be
associated with incident hypertension during long-term
follow-up.Methods
Design and sample. The MESA (Multi-Ethnic Study of
Atherosclerosis) is a prospective study of cardiovascular
disease among 6,814 community-dwelling residents age 45
to 84 years who were free of cardiovascular disease at base-
line. Between 2000 and 2002, participants were recruited
from 6 centers across the United States with different self-
reported ethnical backgrounds (11). Participants with any
previous history of cardiovascular diseases were excluded at
baseline as previously described (11). MESA included 4
follow-up examinations at approximately 18 months, 36
months, 4 years, and 10 years from the baseline examination
between 2002 and 2010, along with periodic telephone
contacts every 6 to 12 months.
We excluded MESA participants who had baseline hy-
pertension, deﬁned as a systolic blood pressure140mmHg,
diastolic blood pressure 90 mm Hg (n ¼ 3,058), or use of
any antihypertensive medication (n ¼ 279). We further
excluded for self-reported hypertension (n ¼ 171), missing
data for anti-hypertension medication use (n ¼ 2), or
inadequate sample volume for measuring 25(OH)D or PTH
(n ¼ 153). None of the remaining participants used lithiummedication or loop diuretics,
which may alter calcium meta-
bolism. Finally, we excluded
participants who did not return
for any follow-up MESA exam-
inations (n ¼ 149), leaving a ﬁnal
analytic sample of 3,002 partici-
pants, free of hypertension at
baseline with complete serum
25(OH)D and PTH measure-
ments (Fig. 1). Compared with
participants excluded, included
participants were younger (58.6
years vs. 64.9 years) and less likely to be black (19.6% vs.
34.2%). Study protocols were approved by the institutional
review board at each participating institution, and all par-
ticipants granted informed consent.
Measurements of vitamin D and PTH. We measured
serum 25(OH)D and PTH concentrations in baseline serum
samples that were collected in the morning after an 8- to 12-h
overnight fast. Samples were stored at 80C and thawed
before analysis in 2011. We measured total serum 25(OH)D
(25OHD2 þ 25OHD3) using liquid chromatography–mass
spectroscopy on a Quattro Micro mass spectrometer (Wa-
ters, Milford, Connecticut) (inter assay CV <3.4%). We
veriﬁed calibration of serum 25(OH)D concentrations using
SRM 972 from the National Institutes of Standards and
Technology. We measured intact serum PTH concentra-
tions using an automated 2-site immunoassay (Beckman-
Coulter, Inc., Brea, California) (interassay coefﬁcient of
variation between 3.4% and 6.1%) (12).
Determination of incident hypertension. MESA study
personnel assessed blood pressure and antihypertensive
medications at each examination. During each examination,
study personnel obtained 3 blood pressure measurements at
5 min apart with the participant seated using an automated
Dinamap sphygmomanometer (Critikon, General Electric,
Madison, Wisconsin). We calculated the mean of the second
2 measurements for analysis. MESA study personnel
instructed participants to bring all of their medications to
each examination, and medication use was assessed by the
inventory method. We deﬁned incident hypertension as a
systolic blood pressure 140 mm Hg, diastolic blood
pressure 90 mm Hg, or the use of any antihypertensive
medication during any of the follow-up examinations.
Covariates. Study personnel collected detailed data re-
garding demographics, comorbidities, and medication use at
enrollment (11). We measured serum phosphate and calcium
to incorporate other important factors of the mineral meta-
bolism in our analyses. We measured serum phosphate using
a timed-rate colorimetry reaction and serum calcium by in-
direct ion selective electrode (12). Participants completed
questionnaires to determine race/ethnicity, smoking status,
alcohol consumption, physical activity, income, and attained
education (11). The highest level of attained education was
categorized into 3 categories: some high school or less,
Figure 1 Flow Diagram of Incident Hypertension Ascertainment for Each Examination Between 2000 to 2010
25(OH)D ¼ 25-hydroxyvitamin D; MESA ¼ Multi-Ethnic Study of Atherosclerosis; PTH ¼ parathyroid hormone.
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1216completed high school, or completed college or more. Body
mass index (BMI, kg/m2) categories were based on measured
height and weight, deﬁned as normal weight (<25 kg/m2),
overweight (25 to 30 kg/m2) and obese (>30 kg/m2). Type 2
diabetes was deﬁned as a reported history of diabetes, use of
any diabetes medication, or a blood glucose level 7 mmol/l
(126 mg/dl). Impaired fasting glucose was deﬁned by a
glucose level of 5.6 to 7.0 mmol/l (100 to 125 mg/dl). Esti-
mated glomerular ﬁltration rate (eGFR) was calculated from
serum calibrated creatinine and cystatin C concentrations
using the Chronic Kidney Disease (CKD) Epidemiology
Collaboration 2012 equation. We deﬁned CKD as
eGFR <60 ml/min/1.73 m2. The Laboratory for Clinical
Biochemistry Research measured high-sensitivity C-reactive
protein (CRP) levels by using the BN II nephelometer
(Siemens, Erlangen, Germany).Statistical Analysis
We adjusted serum 25(OH)D concentrations for season
using methods previously established in MESA (13). We
examined Spearman’s correlations between serum 25(OH)D
and PTH concentrations to describe univariate associations.We tabulated baseline participant characteristics by widely
used categories of 25(OH)D (<20 ng/ml; >20 to 30 ng/ml;
and >30 ng/ml) and by PTH categories that combined
tertiles with a threshold value of 65 pg/ml (<33 pg/ml; >33
to 44.2 pg/ml; >44.2 to 65 pg/ml; >65 ng/ml). The PTH
value of 65 pg/ml represents the upper limit of normal for
this assay based on the central 95% of values from 43 normal
laboratory personnel who had normal 25(OH)D concen-
trations in March 2005 (12). We deﬁned primary hyper-
parathyroidism as a serum PTH concentration 65 pg/ml
plus a serum calcium concentration >10.2 mg/dl (14).
We calculated risk time for incident hypertension as
elapsed time from the baseline examination until the ﬁrst
examination at which incident hypertension was diagnosed,
the last MESA examination, or the last examination before
loss to follow-up, whichever came ﬁrst. We calculated un-
adjusted hypertension rates as the number of events per 100
person-years.
We used a complementary log–log model to estimate
hazard ratios (HRs) for 25(OH)D and PTH with incident
hypertension (15). This model is very similar to a Cox
proportional hazards model, but is able to account for the
time between the discrete time points because the exact date
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1217of the development of hypertension is unknown. To account
for the time that hypertension could occur between the
discrete time intervals, we used interval-censored analyses to
estimate HRs, under the assumption that the hazard is
constant within each interval, but can vary across intervals.
This assumption of piecewise-constant hazards is preferred
for discrete time intervals because risk estimates can change
over time. We used a Wald test to calculate p values and
95% conﬁdence intervals (CIs). Based on visual inspection
of the hazard functions by Schoenfeld residuals, we found no
evidence to contradict the proportionality assumption.
We adjusted serial nested models for demographic vari-
ables and known hypertension risk factors. In the ﬁrst
model, we adjusted for age, sex, race, and clinic site. In the
second model, we added adjustment for smoking (yes/no),
education (3 categories), total family income (5 categories),
diabetes status (3 categories), BMI, low-density lipoprotein
cholesterol, nonsteroidal anti-inﬂammatory medication and
cyclooxygenase-2 inhibitor use, and physical activity. We
further adjustedmodels of PTH for serum 25(OH)D (ng/ml)
because vitamin D deﬁciency is a known risk factor for
hyperparathyroidism. To separately study potential con-
founding by kidney function, we adjusted the ﬁnal model for
urinary albumin creatinine ratio and eGFR. We analyzed
age, BMI, low-density lipoprotein cholesterol, physical ac-
tivity, eGFR, and albumin creatinine ratio as continuous
variables in the multivariate models. Finally, we assessed
dose-response relations of 25(OH)D and PTH with inci-
dent hypertension using restricted cubic spline models
adjusted for covariates speciﬁed in model 3.
We looked for potential effect modiﬁcation by race,
sex, BMI, CKD, and interaction by 25(OH)D with PTH
using interaction terms, and present combined results for the
total study sample if estimates were similar. To test the
stability of the estimates, we conducted several sensitivity
analyses: 1) excluding participants with incident hyperten-
sion diagnosed solely by incident use of antihypertensive
medications because medication may be prescribed to par-
ticipants with diabetes but without hypertension; and 2)
excluding participants with borderline hypertension at
baseline, deﬁned as systolic blood pressure 130 mm Hg
and diastolic blood pressure 85 mm Hg at baseline, for a
meaningful change in blood pressure. We conducted ana-
lyses using IBM SPSS 20.0 for Windows 7 (SPSS Inc.,
Chicago, Illinois).Results
Study sample. Among the 3,002MESA participants, mean
age was 59  9.7 years and 53% were female. After
completing the baseline examination, 2,258 MESA partici-
pants completed all 4 subsequent examinations, 487 partici-
pants completed 3, 151 participants completed 2, and 106
participants completed 1 follow-up examination. Approx-
imately 15% of participants were current smokers, 6% had
type 2 diabetes, 6% hadCKD, and<1% (n¼ 17) had primaryhyperparathyroidism. Excluded participants who did not
attend any follow-up visit (n ¼ 149) were older (61 years vs.
59 years), more likely to be male (53% vs. 47%), had
higher systolic blood pressure (116 mmHg vs. 114 mmHg),
higher prevalence of diabetes (9% vs. 6%), less likely to
be white (28% vs. 43%), and more likely to be Hispanic
(40% vs. 23%).
Description of serum 25(OH)D and PTH concentrations.
The distribution of serum 25(OH)D and PTH concentra-
tions were both unimodal and approximately symmetric, with
mean values of 26.3  11.2 ng/ml and 41.2  17.3 pg/ml.
Serum 25(OH)D concentrations were inversely correlated
with serum PTH concentrations (correlation coefﬁcient
0.34). Lower serum 25(OH)D concentrations were
related to younger age, black and Hispanic race, lower
attained education, higher prevalence of type 2 diabetes,
current smoking, higher BMI, lower high-density lipo-
protein cholesterol, and higher PTH, eGFR, and CRP
concentrations (Table 1). Higher serum PTH concentra-
tions were associated with older age; black and Hispanic
race; higher BMI, systolic blood pressure, and CRP
concentrations; and lower 25(OH)D and phosphate
concentrations.
Incident hypertension. During a median follow-up of 9.0
years (range 1.2 to 11.1 years), 1,229 participants (41%)
developed incident hypertension. The determination of
incident hypertension was made by blood pressure measure-
ments alone in 349 participants, antihypertensive medication
use alone in 249 participants, and both blood pressure and
medication use in 631 participants.
Associations of 25(OH)D with incident hypertension.
Lower serum 25(OH)D categories were associated with
greater unadjusted incident hypertension rates during
follow-up (Table 2). Associations of 25(OH)D with hy-
pertension persisted after minimal adjustments; however,
further adjustment for potential confounders, plus measures
of kidney function, progressively attenuated these associa-
tions, which were no longer statistically signiﬁcant (HR:
1.13 [95% CI: 0.96 to 1.33]). Fully adjusted spline models
of continuous serum 25(OH)D concentrations showed a
tendency toward greater hypertension risks with lower
25(OH)D concentrations, although not statistically signiﬁ-
cant (Fig. 2A).
Associations of 25(OH)D and hypertension were similar
across subgroups deﬁned by age, sex, race, CKD, and PTH
(p for interaction > 0.10). We found evidence for an inter-
action between 25(OH)D categories and BMI categories in
relation to incident hypertension (interaction p < 0.001)
with greater and statistically signiﬁcant risk among obese
participants (BMI range 30 to 52 kg/m2) (Fig. 3A).
However, when adjusting for BMI as a continuous variable
because associations may be driven by the severity of BMI
within the BMI categories, the results attenuated notably
and were no longer signiﬁcant within BMI strata (HR: 1.17
[95% CI: 0.92 to 1.42] for overweight and 1.32 [95% CI:
0.88 to 1.75] for obese participants).
Table 1 Characteristics of 3,002 Participants by Serum 25(OH)D and PTH Concentrations
Serum 25(OH)D (ng/ml)* Serum PTH (pg/ml)*
<20 >20–30 >30 <33 >33–44.2 >44.2–65 >65
Demographic data
n 922 1,028 1,052 1,056 912 789 245
Age, yrs 57.0  9.4 59.0  9.7 60.0  9.8 58.0  9.4 58.0  9.8 60.0  9.7 60.0  10.0
Females 497 (54) 511 (50) 572 (53) 566 (54) 463 (51) 410 (52) 141 (58)
Race
White 204 (22) 441 (43) 661 (63) 540 (51) 407 (45) 287 (36) 72 (29)
Black 391 (43) 139 (14) 58 (5) 125 (12) 173 (19) 208 (26) 82 (34)
Chinese 94 (10) 187 (18) 135 (13) 193 (18) 131 (14) 83 (11) 9 (4)
Hispanic 233 (25) 261 (25) 198 (19) 198 (19) 201 (22) 211 (27) 82 (33)
Highest level of education
Some high school
or less
141 (15) 170 (17) 141 (13) 147 (14) 142 (16) 121 (15) 42 (17)
Completed high school 386 (42) 390 (38) 369 (35) 401 (38) 331 (36) 311 (40) 102 (42)
Completed college
or more
393 (43) 466 (45) 541 (52) 506 (48) 437 (48) 357 (45) 100 (41)
Type 2 diabetes 75 (8) 67 (7) 40 (4) 62 (6) 54 (6) 53 (7) 13 (5)
IFG 131 (14) 112 (11) 77 (7) 91 (9) 98 (11) 95 (12) 36 (15)
CKD 38 (4) 58 (6) 95 (9) 61 (6) 55 (6) 55 (7) 20 (8)
Cigarette smokers 185 (20) 132 (13) 124 (12) 171 (16) 145 (16) 100 (13) 25 (10)
Physical activity
(MET-min/week)
6,703  6,455 5,692  5,509 6,484  6,052 6,254  5,853 6,203  5,859 6,326  6,339 6,577  6,321
BMI, kg/m2 29.0  5.9 27.0  4.6 26.0  4.2 25.9  4.3 27.3  5.0 28.1  5.1 30.0  6.3
SBP, mm Hg 115.0  12.3 114.0  12.9 114.0  13.3 112.0  12.9 114.0  13.0 116.0  12.7 117.0  12.1
DBP, mm Hg 70.0  8.3 69.0  8.6 68.0  8.8 68.0  8.6 69.0  8.8 69.0  8.5 69.0  8.7
Metabolic variables
25(OH)D, ng/ml 14.0  3.8 25.0  2.8 38.0  8.4 30.0  11.3 27.0  10.3 23.0  10.3 19.0  10.1
PTH, pg/ml 49.0  20.8 40.0  15.0 35.0  12.9 26.0  4.8 38.0  3.2 52.0  5.6 81.0  21.6
Calcium, mg/dl 9.6  0.4 9.6  0.4 9.7  0.4 9.7  0.4 9.6  0.4 9.6  0.4 9.6  0.5
Phosphate, mg/dl 3.7  0.5 3.7  0.5 3.7  0.5 3.8  0.5 3.7  0.5 3.6  0.5 3.5  0.5
LDL cholesterol, mg/dl 120.0  34.1 119.0  29.7 118.0  30.1 119.0  29.3 119.0  32.0 121.0  31.5 118.0  34.0
eGFR, ml/min/1.73 m2 93.0  15.4 90.0  15.1 87.0  15.0 90.0  14.6 90.0  15.2 90.0  16.0 89.0  16.4
Triglycerides, mg/dl 125.0  91.0 132.0  104 123.0  73.7 127.0  75.8 131.0  118 123.0  75.7 119.0  66.7
CRP, mg/l 3.9  5.6 2.9  4.7 2.9  4.8 2.9  5.3 3.1  4.6 3.5  4.7 3.9  6.2
Urinary ACR, mg/gy 5.2  2.4 5.0  2.3 4.8  2.2 4.6  2.1 5.0  2.4 5.4  2.4 6.0  2.5
Medication use
Thyroid agents 46 (5) 56 (6) 68 (7) 70 (7) 41 (5) 46 (6) 13 (5)
NSAID 139 (15) 170 (17) 205 (20) 207 (20) 148 (16) 122 (16) 37 (15)
COX-2 inhibitor 42 (5) 37 (4) 51 (5) 43 (4) 32 (4) 43 (6) 12 (5)
Values are mean  SD or n (%). *To convert 25(OH)D values into mmol/l multiply by 2.5; to convert PTH values into pmol/l divide by 9.4. yGeometric mean.
25(OH)D ¼ 25-hydroxyvitamin D; ACR¼ albumin creatinine ratio; BMI ¼ body mass index; CKD¼ chronic kidney disease; COX-2 inhibitor¼ cyclooxygenase-2 inhibitor use; CRP¼ C-reactive protein; DPB ¼
diastolic blood pressure; eGFR ¼ estimated glomerular ﬁltration rate; IFG ¼ impaired fasting glucose; LDL ¼ low-density lipoprotein; MET ¼ metabolic equivalent of task; NSAID ¼ nonsteroidal anti-in-
ﬂammatory drug; PTH ¼ parathyroid hormone; SBP ¼ systolic blood pressure.
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1218Associations of PTH with incident hypertension. In
unadjusted and demographic-adjusted models, higher serum
PTH concentrations were associated with greater rates of
incident hypertension (Table 2). Further adjustment for
potential confounders, including 25(OH)D and different
measures of kidney function attenuated this trend across
PTH categories. However, serum PTH concentrations 65
pg/ml remained associated with incident hypertension in
fully adjusted models (HR: 1.27 [95% CI: 1.01 to 1.59]).
The adjusted spline models were consistent with this obser-
vation, demonstrating greater hypertension risks for serum
PTH concentrations approximately >70 pg/ml (Fig. 2B).For PTH, we also found signiﬁcant interaction with BMI
categories in relation to hypertension (p for interaction
<0.001), with a greater risk for obese participants (Fig. 3B).
After adjusting for BMI as a continuous variable, the
associations were no longer statistically signiﬁcant: HR:
1.23 (95% CI: 0.83 to 1.63) for overweight and 1.38
(95% CI: 0.92 to 1.74) for obese participants. Associations
of PTH with incident hypertension were similar across
subgroups of age, sex, race, CKD, and 25(OH)D. Adjust-
ment for mineral metabolism markers including calcium
and phosphate did not appreciably change the observed
associations.
Table 2 Associations of Serum 25(OH)D and PTH With Incident Hypertension Among 3,002 Participants
Mineral Metabolism
Markers n Cases
Incidence Rates per
100 Person-Years Model 1 Model 2 Model 3
25(OH)D <20 ng/ml 922 414 (44.9) 6.7 1.28 (1.09–1.50) 1.17 (0.99–1.38) 1.13 (0.96–1.33)
25(OH)D 20–30 ng/ml 1,028 428 (41.6) 6.2 1.23 (1.06–1.41) 1.14 (0.98–1.32) 1.14 (0.98–1.31)
25(OH)D >30 ng/ml 1,052 387 (36.8) 5.2 Ref Ref Ref
p for trend <0.001 0.003 0.140 0.199
PTH <33 pg/ml 1,056 384 (36.4) 5.1 Ref Ref Ref
PTH 33–44.2 pg/ml 912 361 (39.6) 5.7 1.03 (0.90–1.19) 1.02 (0.87–1.19) 1.00 (0.86–1.17)
PTH 44.2–65 pg/ml 789 359 (45.5) 6.9 1.16 (1.00–1.35) 1.11 (0.95–1.30) 1.09 (0.94–1.28)
PTH 65 pg/ml 245 125 (51.0) 8.1 1.36 (1.10–1.68) 1.30 (1.03–1.64) 1.27 (1.01–1.59)
p for trend <0.001 0.016 0.124 0.150
Values are n (%) or adjusted hazard ratio (95% conﬁdence interval) unless otherwise indicated. Model 1 is adjusted for age, sex, race, and clinic site. Model 2 is model 1 þ smoking, education, income,
diabetes status, body mass index, low-density lipoprotein, nonsteroidal anti-inﬂammatory drug use, cyclooxygenase-2 inhibitor use, physical activity (in case of PTH, adjusted for 25[OH]D). Model 3 is model
2 þ albumin creatinine ratio and estimated glomerular ﬁltration rate.
25(OH)D ¼ 25-hydroxyvitamin D; PTH ¼ parathyroid hormone; Ref ¼ reference category.
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1219Sensitivity analyses. After excluding 248 participants who
had incident hypertension diagnosed solely by use of
antihypertensive medications, the adjusted associations of
25(OH)D and PTH with hypertension were numerically
similar. Similarly, excluding the 444 participants who had
borderline hypertension at baseline or the 17 participants
who had evidence of primary hyperparathyroidism did not
appreciably change these associations.
Discussion
In this study, we report associations of serum 25(OH)D and
PTH with incident hypertension in a large, multi-ethnic
cohort during 9 years of follow-up. Lower 25(OH)D was
associated with greater hypertension risk, although the as-
sociation became nonsigniﬁcant after adjusting for potential
confounders. In contrast, higher serum PTH remained
signiﬁcantly associated with a greater risk of incident hy-
pertension after adjustments. These ﬁndings suggest thatFigure 2 Continuous Associations of 25(OH)D and PTH Concentratio
Adjusted dose-response relations of serum 25-(OH)D (A) and PTH (B) concentrations withigher PTH concentrations might play a role in the path-
ogenesis of developing hypertension. These associations may
underlie the increased risk for cardiovascular disease among
participants with high PTH (16).
Previous studies that investigated circulating 25(OH)D
concentrations and hypertension risk are sparse and showed
inconsistent results. In a case-control study among young
women, lower plasma 25(OH)D was signiﬁcantly associated
with self-reported hypertension risk (6), although the sample
excluded obese women and almost two-thirds of the women
were vitamin D deﬁcient. Another study showed that plasma
25(OH)D was inversely associated with self-reported inci-
dent hypertension in a subsample of older men and women,
and the risk estimates for predicted 25(OH)D concentra-
tions showed stronger estimates in the larger sample (7). It
should be noted that most participants had only predicted
25(OH)D values, the study did not include measured
blood pressure, and conﬁdence intervals were wide. Differ-
ences in study design, ascertainment of hypertension, andns With Incident Hypertension
h incident hypertension. Abbreviations as in Figure 1.
Figure 3 Associations of 25(OH)D and PTH With Incident Hypertension by BMI categories
Associations between categories of 25-(OH)D (A) and PTH (B) with incident hypertension within 3 different body mass index (BMI) categories. CI ¼ conﬁdence interval;
other abbreviations as in Figure 1.
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pared with our study.
Our study conﬁrms previous work that showed weak in-
verse relationships between circulating 25(OH)D concen-
trations and measured incident hypertension risk among a
Norwegian sample that included a broad age spectrum of
men and women (17), a large cohort of post-menopausal
women (9), and Finnish middle-aged male smokers (10).
The inconsistent results for 25(OH)D and incident hyper-
tension indicate that the relationship between 25(OH)D
and hypertension risk is less clear. Intervention trials that
investigated vitamin D supplementation and blood pressure
are scarce. A study among post-menopausal women reported
that daily supplementation of calcium (1,200 mg) and cal-
cium and vitamin D (800 IU) for 8 weeks reduced systolic
blood pressure by 8 mm Hg (18). In a dose-response study
in black patients, 3 months of vitamin D supplementation
(1,000/2,000/4,000 IU) signiﬁcantly lowered systolic blood
pressure in a dose-dependent manner (19). Other studies
did not observe effects of vitamin D on blood pressure
among different populations (20–22). These clinical trials of
vitamin D supplementation have been limited by inadequate
vitamin D dosage, insufﬁcient duration of therapy, and the
use of bolus therapy to replete vitamin D. Moreover, our
results should be interpreted in the growing recognition of
heterogeneity of response to vitamin D deﬁciency, according
to variation in vitamin D metabolism genes (23,24).
Previous studies that investigated PTH and hypertension
risk showed similar risk estimates as ours (3,4). Among
older men, plasma PTH concentrations were positivelyassociated with hypertension risk (3). Anderson et al. (4)
reported that higher PTH was borderline associated with
incident hypertension in an older population (HR: 1.50
[95% CI: 0.99 to 2.24]) (4).
Taken together, our study provides further evidence for an
association between higher PTH concentrations and future
hypertension risk in different ethnic groups. Hypertension
contributes to the development of vascular aging and is a
major risk factor for cardiovascular diseases. Moreover, in
the MESA study, serum PTH was cross-sectionally asso-
ciated with endothelial dysfunction and arterial stiffness, and
may partially explain associations of elevated serum PTH
with hypertension risk (12).
Although we can only speculate on potential mechanisms,
several important observations regarding the biologic actions
of PTH warrant discussion. The fact that serum PTH was
associated with greater hypertension risk after adjustment for
25(OH)D suggests that PTH, independent of 25(OH)D,
contributes to the development of hypertension. Multiple
mechanisms may explain how PTH might inﬂuence the
vasculature. Recent evidence suggests that there is an
interaction between aldosterone and PTH by modulating
angiotensin signaling (5). Furthermore, circulating PTH
may affect intracellular signaling, causing intracellular cal-
cium overload and leading to severe cell injury and death
(25,26). Also, PTH stimulates the renin-angiotensin system
(27). Among 123 ambulatory older adults undergoing 24-h
blood pressure monitoring, higher PTH levels were inde-
pendently related with higher blood pressure (28). Among
85 women selected from a population-based study, higher
JACC Vol. 63, No. 12, 2014 van Ballegooijen et al.
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1221PTH levels were related with both higher systolic and dia-
stolic blood pressure (29). One potential mechanism is that
PTH excess, by precipitating increases in blood pressure,
may predispose individuals to a higher risk of hypertension
and eventually cardiovascular disease (30). The complexity of
the mineral metabolism makes it hard to fully disentangle
the individual contribution of these factors to the vasculature
and warrants further investigation.
In our study, we found a signiﬁcant interaction of
25(OH)D and PTH with BMI categories. In obese par-
ticipants, but not in overweight and normal-weight per-
sons, lower 25(OH)D and higher PTH concentrations
were associated with incident hypertension (Fig. 3).
However, after adjustment for BMI as a continuous vari-
able within each BMI stratum, the association in obese
persons attenuated and was no longer signiﬁcant, suggesting
residual confounding due to BMI in this group. Inter-
vention studies have shown a lower impact of vitamin D
supplementation on serum 25(OH)D concentrations in
obese versus normal-weight individuals among different age
and ethnic groups (31,32) and increased concentrations
after weight loss (33). These trials indicate that vitamin D
concentrations are likely to be dependent on adiposity and
could explain the observed associations with higher BMI
categories due to a greater fat mass. This could be due to
changes in serum leptin, FGF-23, or bone alkaline phos-
phatase concentrations (34). Adjusting for BMI led to
signiﬁcant attenuation of the associations, suggesting that
BMI is a very important factor, even within BMI strata,
that should be taken into account when studying these
relationships.
Strengths of our study are the use of a large, community-
based cohort without pre-existing cardiovascular or prevalent
hypertension at baseline and a considerable length of follow-
up. To our knowledge, this is the ﬁrst study that simulta-
neously assessed the relationship of serum 25(OH)D and
PTH with incident hypertension. These ﬁndings add new
knowledge to underlying subclinical cardiovascular disease
mechanisms and strengthen the case for disturbances in high
PTH as a cardiovascular risk factor. We studied a multi-
ethnic cohort that allows generalization to other ethnicities,
although generalization to younger age groups should be
done with caution because the pathophysiology may differ
between age groups. Additionally, we used standardized
methods to assess serum 25(OH)D and PTH, hypertension
risk factors, several measures of kidney function, and co-
morbid conditions, therein minimizing the possibility of re-
sidual confounding.
Study limitations. Important limitations include possible
misclassiﬁcation of hypertension, ascertainment of hyper-
tension at discrete time points, and the potential for con-
founding by measurement error in available characteristics.
These concerns are to some extent mitigated by sensitivity
analyses demonstrating robust associations with only minor
changes in the magnitude between serum 25(OH)D and
PTH in relation to incident hypertension. The observationaldesign does not conﬁrm causal relationships with incident
hypertension and residual confounding by unmeasured
characteristics that cannot be excluded. Exposure mar-
kersdserum 25(OH)D and PTHdwere assessed at base-
line (2000 to 2002), and changes in exposure over time can
lead to misclassiﬁcation; however, the prospective design
favors nondifferential misclassiﬁcation, which would most
likely dilute the observed associations. Future studies should
conﬁrm whether the observed associations are similar for
younger individuals.
Conclusions
We report associations of higher PTH concentrations
with greater incident hypertension in a community-based,
middle-aged, multi-ethnic cohort. Vitamin D–deﬁciency
and PTH excess are common ﬁndings among the general
population, and a better understanding of the clinical impli-
cations of the pathogenesis of hypertension may help to
promote cardiovascular health.
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